Severe acute respiratory syndrome‐coronavirus‐2: Current advances in therapeutic targets and drug development

Suganya, S.; Divya, S.; Parani, Madasamy

doi:10.1002/rmv.2174

Cited by 7 publications

(5 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A good number of these patients (95–100%) demonstrate neutralizing activity 14 days after the onset of COVID-19 symptoms. The neutralizing activities exhibited include IgM, IgG, and antibodies targeting RBD of SARS-CoV-2 ( Suganya, Divya, & Parani, 2021 ; Zhao et al, 2020 ). NAbs elicit humoral responses in the host immune system, inhibiting the SARS-CoV-2 binding to the human receptor, in addition to instigating viral lysis through antibody-mediated opsonization or complement activation ( Jiang, Hillyer, & Du, 2020 ; Suganya et al, 2021 ).…”

Section: Relevant Sars-cov-2 Antigen Explored In the Design Of Vaccinesmentioning

confidence: 99%

“…Unlike the S protein, few studies have focused on SARS-CoV-2 M protein (S2M) ( Suganya et al, 2021 ). The function of the M protein starts with the assembly of viral particles and the initiation of its budding process ( Ahmad et al, 2021 ; Zarandi et al, 2021 ), as well as membrane stabilization functions ( Young et al, 2021 ).…”

Section: Relevant Sars-cov-2 Antigen Explored In the Design Of Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

Recent and advanced nano-technological strategies for COVID-19 vaccine development

Nwagwu

Ugwu

Ogbonna

et al. 2022

Covid-19: Biomedical Perspectives

View full text Add to dashboard Cite

Section: Relevant Sars-cov-2 Antigen Explored In the Design Of Vaccinesmentioning

confidence: 99%

Section: Relevant Sars-cov-2 Antigen Explored In the Design Of Vaccinesmentioning

confidence: 99%

Recent and advanced nano-technological strategies for COVID-19 vaccine development

Nwagwu

Ugwu

Ogbonna

et al. 2022

Covid-19: Biomedical Perspectives

View full text Add to dashboard Cite

“…The RdRp (nsp12) has also been described as an important coronavirus target for drug design [ 41 , 44 , 45 ]. It has an essential role in the viral cycle of coronaviruses, since it is responsible for the replication of the viral genome, with the assistance of nsp7 and nsp8 viral proteins in a polymerase complex [ 39 , 94 , 95 ].…”

Section: The Importance Of Multitargets To Cadd Approaches: Pl mentioning

confidence: 99%

Knowing and combating the enemy: a brief review on SARS-CoV-2 and computational approaches applied to the discovery of drug candidates

et al. 2021

View full text Add to dashboard Cite

Since the emergence of the new severe acute respiratory syndrome-related coronaviruses 2 (SARS-CoV-2) at the end of December 2019 in China, and with the urge of the coronavirus disease 2019 (COVID-19) pandemic, there have been a huge effort of many research teams and governmental institutions worldwide to mitigate the current scenario. Reaching more than 1,377,000 deaths in the world and still with a growing number of infections, SARS-CoV-2 remains a critical issue for global health and economic systems, with an urgency for available therapeutic options. In this scenario, as drug repurposing and discovery remains a challenge, computer-aided drug design (CADD) approaches, including machine learning (ML) techniques, can be useful tools to the design and discovery of novel potential antiviral inhibitors against SARS-CoV-2. In this work, we describe and review the current knowledge on this virus and the pandemic, the latest strategies and computational approaches applied to search for treatment options, as well as the challenges to overcome COVID-19.

show abstract

“…In late 2021, India faced massive surge of COVID-19 cases. From the start of the pandemic, many attempts were made to spot the possible drugs against this disease [2][3][4][5]. With the great effort of the scientific community, many FDA/WHO-approved drugs are now available to combat the severity associated with SARS-CoV-2 infection.…”

Section: Introductionmentioning

confidence: 99%

Plant-derived immuno-adjuvants in vaccines formulation: a promising avenue for improving vaccines efficacy against SARS-CoV-2 virus

et al. 2022

View full text Add to dashboard Cite

The SARS-CoV-2 outbreak has posed a plethora of problems for the global healthcare system and socioeconomic burden. Despite valiant efforts to contain the COVID-19 outbreak, the situation has deteriorated to the point that there are no viable preventive therapies to treat this disease. The case count has skyrocketed globally due to the newly evolved variants. Despite vaccination drives, the re-occurrence of recent pandemic waves has reinforced the importance of innovation/utilization of immune-booster to achieve appropriate long-term vaccine protection. Plant-derived immuno-adjuvants, which have multifaceted functions, can impede infections by boosting the immune system. Many previous studies have shown that formulation of vaccines using plant-derived adjuvant results in long-lasting immunity may overcome the natural tendency of coronavirus immunity to wane quickly. Plant polysaccharides, glycosides, and glycoprotein extracts have reportedly been utilized as enticing adjuvants in experimental vaccines, such as Advax, Matrix-M, and Mistletoe lectin, which have been shown to be highly immunogenic and safe. When employed in vaccine formulation, Advax and Matrix-M generate long-lasting antibodies, a balanced robust Th1/Th2 cytokine profile, and the stimulation of cytotoxic T cells. Thus, the use of adjuvants derived from plants may increase the effectiveness of vaccines, resulting in the proper immunological response required to combat COVID-19. A few have been widely used in epidemic outbreaks, including SARS and H1N1 influenza, and their use could also improve the efficacy of COVID-19 vaccines. In this review, the immunological adjuvant properties of plant compounds as well as their potential application in anti-COVID-19 therapy are thoroughly discussed.

show abstract

Severe acute respiratory syndrome‐coronavirus‐2: Current advances in therapeutic targets and drug development

Cited by 7 publications

References 91 publications

Recent and advanced nano-technological strategies for COVID-19 vaccine development

Recent and advanced nano-technological strategies for COVID-19 vaccine development

Knowing and combating the enemy: a brief review on SARS-CoV-2 and computational approaches applied to the discovery of drug candidates

Plant-derived immuno-adjuvants in vaccines formulation: a promising avenue for improving vaccines efficacy against SARS-CoV-2 virus

Contact Info

Product

Resources

About